Skye Bioscience

SKYE · NASDAQ

$1.62+$0.09 (+5.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.53

SKYE analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Mar 20, 2026

Bull case

Skye Bioscience Inc. is advancing the development of nimacimab, an innovative therapy targeting peripheral CB1 receptors, which shows promise for broader applications in metabolic liver disease and obesity due to its favorable biomarker improvements and liver-targeting properties. This potential expansion into areas beyond initial indications, similar to the progression of ezetimibe, suggests a strategic advantage in addressing comprehensive cardiometabolic risks. Additionally, the gastrointestinal tolerability of nimacimab compared to GLP-1 agonists supports the potential for sustained patient adherence, further enhancing the therapeutic prospects and commercial viability of the company's clinical pipeline.

Bear case

Skye Bioscience has consistently incurred operating losses since its inception, which indicates potential challenges in achieving profitability for several years. Furthermore, if the Phase 2a trial for nimacimab yields limited efficacy or safety concerns, it could render the drug non-viable for obesity treatment, leading to a significant decline in stock value, possibly down to cash value. Lastly, the noted translational gaps in safety and tolerability for CB1 antagonists, particularly due to their central nervous system penetration, add an additional layer of risk to the company's clinical assets and overall market outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.